(MedPage Today) — Patients who underwent stem cell transplants (SCTs) involving mismatched unrelated donors (MMUDs) had a 1-year overall survival (OS) of about 80% with post-transplant cyclophosphamide (PTCy)-based prophylaxis for graft-versus…
Source link : https://www.medpagetoday.com/hematologyoncology/hematology/116263
Author :
Publish date : 2025-06-26 16:04:00
Copyright for syndicated content belongs to the linked Source.
